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Abstract
Sos1 is an universal, widely expressed Ras guanine nucleotide-exchange factor (RasGEF) in eukaryotic cells. Its N-
terminal HD motif is known to be involved in allosteric regulation of Sos1 GEF activity through intramolecular
interaction with the neighboring PH domain. Here, we searched for other cellular proteins also able to interact
productively with the Sos1 HD domain. Using a yeast two-hybrid system, we identified the interaction between the
Sos1 HD region and CSN3, the third component of the COP9 signalosome, a conserved, multi-subunit protein
complex that functions in the ubiquitin–proteasome pathway to control degradation of many cellular proteins. The
interaction of CSN3 with the HD of Sos1 was confirmed in vitro by GST pull-down assays using truncated mutants and
reproduced in vivo by co-immunoprecipitation with the endogenous, full-length cellular Sos1 protein. In vitro kinase
assays showed that PKD, a COP9 signalosome-associated-kinase, is able to phosphorylate Sos1. The intracellular levels
of Sos1 protein were clearly diminished following CSN3 or PKD knockdown. A sizable fraction of the endogenous Sos1
protein was found ubiquitinated in different mammalian cell types. A significant reduction of RasGTP formation upon
growth factor stimulation was also observed in CSN3-silenced as compared with control cells. Our data suggest that
the interaction of Sos1 with the COP9 signalosome and PKD plays a significant role in maintenance of cellular Sos1
protein stability and homeostasis under physiological conditions and raises the possibility of considering the CSN/PKD
complex as a potential target for design of novel therapeutic drugs.
Introduction
Ras proteins are small GTPases acting as molecular
switches to connect various extracellular signals to
intracellular pathways that modulate cellular prolifera-
tion, differentiation, senescence or death. They are con-
tinuously cycling between inactive (Ras-GDP) and active
(Ras-GTP) conformations through a process modulated
by negative (GTPase activating proteins, GAPs) and
positive (guanine nucleotide-exchange factors, GEFs)
regulators. The Sos1 and Sos2 proteins constitute the
most universal and widely expressed family of RasGEFs in
mammalian cells1–6.
The highly homologous, ubiquitously expressed Sos1
and Sos2 proteins7,8 exhibit a multi-modular structure
featuring conserved distribution of specific, functional
domains along their amino-, central-, or carboxy-terminal
regions1,5,6. The carboxyl-terminal end of Sos proteins is a
proline-rich (PR) region adopting left-handed type II helix
conformation9–11, which binds the SH3 domains of
Grb28,12,13. Two distinct hSos1 isoforms differing in their
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Grb2-binding ability and biological potency have been
identified in this region14,15. The amino-terminal region
of Sos proteins includes the histone-like domain (HD),
Dbl-homology domain (DH), pleckstrin domain (PH), and
helical linker (HL)6. The Ras-Exchange motif (REM) and
the CDC25-homology (CDC25-H) domains are located
centrally, between the HL domain and the PR motif, and
constitute the catalytic-center of the nucleotide-exchange
activity on Ras proteins16. Interaction of the REM domain
with the switch-2 region of Ras mediates binding to Ras-
GDP whereas, simultaneously, connection of the two β-
sheets of the CDC25H domain with the switch-1 region of
Ras promotes dissociation of GDP17.
Various structural studies indicate that the amino-
terminal region plays a role in allosterical regulation of the
overall RasGEF activity of Sos6,18,19. This N-terminal
region concentrates most of the activating (gain-of-
function) Sos1 germline mutations detected in Noonan
syndrome cells20,21, where hyperactivation of Ras is the
result of reduced Ras-GEF self-inhibition6. The HD region
shows high homology to histone H2A and contains two
tandem histone folds19. Structural studies have shown
that the HD stabilizes the self-inhibited conformation of
Sos proteins through its basal conformational interaction
with the DH-PH region22. In this conformation, the DH-
PH domain blocks the Ras allosteric binding site17,22 and,
only after the stimulation by growth factors, the complete
activation of Sos may proceed. This activation requires
growth-factor-induced generation of phosphatidic acid via
phospholipase D223 followed by recruitment of Sos to the
plasma membrane through the PH domain6 and HD
binding to phosphatidic acid, thus promoting Sos RasGEF
activity in the plasma membrane24.
Based on the HD tertiary structure and its function as a
modulator of Sos-GEF activity, we hypothesized that this
domain could interact in vivo with some cellular proteins
in order to regulate Sos RasGEF overall functionality.
Here, we demonstrate in vitro and in vivo interaction
between the HD of Sos1 and CSN3, a subunit of the
highly conserved COP9 signalosome complex25 and also
show experimental evidences supporting the functional
relevance of this HD-mediated interaction, indicating that
the COP9 signalosome and its associated PKD contribute
to regulating the half-life and homeostasis of cellular Sos1
protein and therefore the activity of the Ras signaling
pathway.
Results
CSN3 interacts with the HD of Sos1 in a yeast two-hybrid
system
To identify candidate cellular proteins able to interact
with the amino-terminal region of hSos1, we performed
yeast two-hybrid screens using a host strain (EGY48,
harboring both LacZ and Leu reporter genes under
control of LexA) that was co-transformed with a HeLa
cDNA plasmid library (clones fused to B42-activation
domain) and different plasmid baits coding for various
truncated fragments of the N-terminal region of hSos1
(fused to LexA-DNA-binding domain) (Fig. 1a). As
internal control, we confirmed previously that none of the
hSos1 amino-terminal fragments tested could by itself and
alone activate transcription of the reporter genes (Fig. 1b),
and we also assessed that the LexA-fusion peptides cor-
rectly reached the nucleus of our yeast host strain EGY48
(data not shown).
Initial screening using a LexA-NDP plasmid bait coding
for the first 548 amino-terminal residues of hSos1 yielded
high numbers of positive, interacting clones. After suc-
cessive rounds of screening, two clones showing positive
interactions were selected for further study (Fig. 1c). After
DNA sequencing, we found that in both cases the target
cDNAs coded for the COP9 signalosome complex subunit
3 protein (CSN3) (NP_001303284.1).
In order to determine whether any specific subdomain
within the NDP region was specifically responsible for the
interaction with CSN3, we performed additional two-
hybrid screenings testing the interaction between our
positive cDNA clones coding different LexA-fused pep-
tide subdomains (HD, NDP, DH, PH, DH-PH) of the NDP
region (Fig. 1c). As internal control, we also tested in
these assays a similar LexA-fusion construct coding for
the C-terminal PRII region of hSos1, which is responsible
for interaction with the Grb2 adaptor protein. Positive
interactions occurring between CSN3 and the different
peptide subdomains tested in these assays were revealed
by the β-galactosidase activity (blue color) and the growth
of the corresponding yeast clones in culture medium
lacking leucine (Fig. 1c, d). Control clones co-transformed
with both PRII and CSN3, or clones harboring CSN3
alone or the hSos1 N-terminal peptide subdomains alone,
did not elicit any β-galactosidase activity (Fig. 1b, c) and
did not grow on Leu− plates (Fig. 1c, d). In contrast,
transformants containing both CSN3 and HD showed
high levels of β-galactosidase activity (Fig. 1c) and grew
significantly on Leu− medium (Fig. 1d). Judging by level of
β-galactosidase activity and growth on Leu− plates, the
degree of interaction between CSN3 and the HD peptide
was significantly high in the co-transformed yeast clones
expressing both peptides, whereas the target–bait inter-
action appeared to be a bit weaker in those clones har-
boring CSN3 and the NDP peptide (Fig. 1c, d). In
contrast, co-transformants harboring CSN3 and any of
the DH, PH, DH-PH, or PRII peptides did not elicit any
detectable β-galactosidase activity (Fig. 1c) and did not
grow well on Leu− plates (Fig. 1d). The specificity of our
conclusions was validated by our use of an on/off model
in these assays (β-galactosidase activity and LEU+ phe-
notypes detected only in yeast colonies grown on
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galactose-raffinose medium [on-state, induced expression
of B42-CSN3]; and undetectable when growing on glu-
cose medium [off-state, no expression of B42-CSN3]) (Fig.
1d).
These observations in a two-hybrid system strongly
suggest that cellular CSN3 is able to bind to the amino-
terminal region of hSos1, and that this molecular inter-
action specifically involves the HD region/domain of Sos1
protein.
In vitro binding of HD and NDP peptides from the amino-
terminal region of hSos1 to cellular CSN3
To directly validate our yeast two-hybrid findings and
confirm the ability of CSN3 to bind to different hSos1 N-
terminal fragments/domains, we carried out in vitro
binding experiments using pull-down assays. Cytoplasmic
extracts from HeLa cells were incubated with purified
GST-HD, GST-DH-PH, and GST-NDP fusion proteins
coupled to glutathione–sepharose beads that were sub-
sequently tested by means of immunoblotting with anti-
bodies against CSN3 (Fig. 2a). Whereas purified GST-
DHPH did not bind any CSN3, the GST-HD and GST-
NDP peptides bound roughly similar amount of cellular
CSN3 in lysates of actively growing HeLa cells (Fig. 2a,
upper panel). Ponceau staining (Fig. 2a lower panel)
showed similar levels of the peptides in all cases, con-
firming that the HD and NDP regions of hSos1 are able to
bind in vitro to CSN3 from cellular lysates, whereas the
DH and PH domains of hSos1 do not possess such an
interaction capability.
In vivo binding of the cellular COP9 signalosome to
individual peptides of the N-terminal region of hSos1 or
the full-length, endogenous mSos1 protein
CSN3 is a component of the multi-protein cellular
COP9 signalosome complex26 and, in view of our two-
hybrid data and in vitro binding observations, we wished
to ascertain if the interaction between the N-terminal
region of Sos1 (NDP peptide) and the COP9 signalosome
occurs also in vivo, and the status of cell stimulation
under which such an interaction may occur.
For this purpose, we initially used HeLa cells that were
transiently transfected with an epitope-tagged (HA) NDP
construct. Direct cytoplasmic lysates, or immunoprecipitates
Fig. 1 Interaction between CSN3 and hSos1 N-terminal fragments in a yeast two-hybrid system. a Scheme of the primary structure of the
truncated fragments of hSos1. b The constructs in pEG202 coding respectively for the LexA fused to the HD or NDP and vector pJG4-5 alone (without
CSN3) do not present β-galactosidase activity in X-Gal plates assays. Three independent colonies from each co-transformation were analyzed. c B42-
activation domain fusion plasmid coding for B42-CSN3 (construct in pJG4-5) was co-transformed into yeast strain EGY48 (ura3, his3, trp1, LexAop-
leu2) with the plasmid pSH18-34 (LacZ reporter with LexA-binding sites) and with LexA DNA binding domain fusion plasmids (constructs in pEG202)
coding respectively for the LexA fused to the same HD, DH, PH, DH-PH, NDP fragments and for the PRII region of hSos1 (negative control). As others
negative controls, plasmid pEG202 was co-transformed with pJG4-5-CSN3 (Vector+ CSN3). Three independent colonies from each co-transformation
were analyzed for β-galactosidase activity in color X-Gal plates assays. The specificity of the interactions was tested by dependence to galactose-
raffinose. d LEU+ phenotype by patching these colonies in medium lacking leucine
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Fig. 2 Sos1 protein interacts with the multi-protein complex COP9 signalosome. a Binding of cellular CSN3 to GST-DH-PH, GST-HD and GST-
NDP fusion proteins in cell-free extracts. HeLa cell-free extracts were incubated with 20 μg of GST, GST-DH-PH, GST-HD, and GST-NDP proteins
coupled to glutathione–sepharose beads. After washing, cellular proteins bound to the beads were resolved in SDS-PAGE alongside the
corresponding cell extract and immunoblotted against anti-CSN3 antibodies. Lower part shows Ponceau staining showing the expression of GST,
GST-HD, GST-DH-PH, and GST-NDP fusions bound to the membrane prior to western blot analyses. b In vivo interaction between the NDP region of
hSos1 and the COP9 signalosome. Cell extracts from transiently transfected HeLa cells overexpressing NDP with HA epitope tag were starved for 16 h
and stimulated with fetal calf serum for 10 min, then cell extracts were incubated with anti-CSN7a polyclonal rabbit antibody or with unspecific rabbit
IgG. The anti-CSN7a immunoprecipitates or whole-cell extracts (WE) were then analyzed by immunoblotting using anti-HA monoclonal antibody as
described in Materials and methods. c In vivo interaction of the endogenous full-protein Sos1 with the COP9 signalosome. Cell extracts from mouse
embryonic cells Sos2-KO, serum deprived and stimulated with fetal calf serum for 10 min, were incubated with anti-CSN7a rabbit polyclonal antibody
or with unspecific rabbit IgG. The anti-CSN7a immunoprecipitates or whole cell extracts were then analyzed by immunoblotting using anti-Sos1
mouse monoclonal antibody as described in Materials and methods. d Interaction between Sos1 and CSN3 in HeLa cells. Cell lysates or
immunoprecipitates thereof generated using Sos1 antibodies or non-specific IgG were then immunoblotted (IB) with anti-Sos1 or anti-CSN3
antibodies, as indicated. e Interaction between Sos1 and CSN3 in mouse embryo fibroblasts (MEFs). Anti-CSN3 immunoprecipitates of lysates from
wild type (WT) or Sos1fl/fl primary MEFs that were kept untreated (-TAM) or treated (+ TAM) with tamoxifen in order to deplete Sos1 were submitted
to western immunoblots (IB) using the indicated anti-Sos1 or anti-CSN3 antibodies. Pierce® Crosslink Immunoprecipitation Kit (ThermoFisher) was
used for panels d and e, in order to avoid signal interference from the immunoglobulin heavy chains. f Detection of Sos1 ubiquitination. Direct
cell lysates (WE) or anti-ubiquitin immunoprecipitates thereof (IP: anti-Ubiquitin) obtained from wild type (WT), and tamoxifen-induced Sos1-KO or
Sos1/2-DKO primary MEFs were further submitted to immunoblotting (IB) using anti-Sos1, anti-Sos2 or anti-Ubiquitin antibodies, as indicated
Zarich et al. Oncogenesis             (2019) 8:2 Page 4 of 11
Oncogenesis
thereof using polyclonal rabbit anti-CSN7a antibody or
control unspecific IgG, were subsequently probed by
immunoblotting with anti-HA antibodies (Fig. 2b). Notice
that anti-CSN7a antibody was used here as this antibody is
able to immunoprecipate the whole COP9 complex,
including its CSN3 component protein27 and therefore this
approach would not compromise any potential, putative
CSN3-Sos1 interaction. These WB data clearly
Fig. 3 (See legend on next page.)
Zarich et al. Oncogenesis             (2019) 8:2 Page 5 of 11
Oncogenesis
demonstrated the interaction of the COP9 signalosome with
the endogenously overexpressed HA-NDP peptide in both
serum-starved or serum-stimulated HeLa cells (Fig. 2b).
We also wanted to evaluate the ability of the
COP9 signalosome to recognize and interact with endo-
genous, full-length cellular Sos1 protein (Fig. 2c). In this
case, we used Sos2-KO mouse embryonic fibroblasts
(MEFs)28 so as to exclude any potential interference by the
highly homologous Sos2 protein. Cultures of these MEFs
were starved before FCS stimulation and then direct cellular
lysates or immunoprecipitates of the same lysates using
anti-CSN7 antibodies were probed by WB immunoblotting
with anti-Sos1 antibodies (Fig. 2c). These assays consistently
detected the presence of Sos1 in the COP9 immunopreci-
pitates. In addition, the amount of co-immunoprecipitated
Sos1 appeared to be significantly higher in lysates of serum-
stimulated as compared with serum-starved MEFs (Fig. 2c).
Further confirmatory evidence supporting the in vivo
interaction between Sos1 and the COP9 signalosome was
obtained in similar, complementary assays using antibodies
against CSN3 and Sos1 on lysates of cultured mouse
NIH3T3 (not shown) or human HeLa cells (Fig. 2d), as well
as of primary MEFs derived fromWT or conditional, TAM-
inducible, Sos1-KO mice (Fig. 2e).
The interaction of Sos1 with the COP9 signalosome
suggested the possible processing of cellular Sos1 through
the Ubiquitin–Proteasome system (UPS). As ubiquitina-
tion is central to the UPS in order to generate degradation
signals on substrates destined for destruction29, we used
immunoblot assays to look for this possible postransla-
tional modification of Sos1 in primary, WT or Sos1-
depleted MEFs30–32. Our WB data showed that a sizeable
portion of the endogenous Sos1 was found ubiquitinated
in the lysates of primary MEFs growing under normal
conditions in culture (Fig. 2f).
CSN3 knockdown expression reduces Sos1 protein stability
The COP9 signalosome (CSN) is a conserved protein
complex with isopeptidase activity that controls
eukaryotic protein degradation through the UPS by reg-
ulating the activity of cullin-RING ligase (CRL) families of
ubiquitin E3 complexes. Multiple reports document the
involvement of CSN in different cellular and develop-
mental processes, including DNA-damage responses or
control of gene expression and the cell cycle33–35.
To examine whether Sos1 protein stability/homeostasis
is affected by the COP9 signalosome, we knocked-down
CSN3 expression in MEFs from mSos2-KO mice using
specific siRNAs (Fig. 3). Transfection of these MEFs with
a pool of four specific siRNAs covering a portion of the
mouse CSN3 coding sequence resulted in a significant
decrease (about 80%) of endogenous CSN3 expression as
compared with MEFs transfected with control, scrambled
siRNA (Fig. 3a). To investigate the long-term stability of
cellular Sos1, the same mSos2-KO MEFs cells were
incubated in absence or presence or cycloheximide (CHX)
for up to 9 h, and the decay of the Sos1 protein was fol-
lowed over time by WB immunoblotting using anti-Sos1
antibody (Fig. 3b). Quantitation of the mSos1 signal in the
immunoblots showed that CSN3 silencing was associated
with detection of significantly decreased levels of cellular
mSos1 protein in the CHX-treated cells, whereas in
control cells the mSos1 levels remained basically unal-
tered (Fig. 3c). These data indicate that Sos1 protein
durability diminishes following CSN3 knockdown and
suggest that the COP9 signalosome participates in
regulation of the stability of cellular Sos1 protein.
As a known function of the COP9 signalosome is the
control of proteolysis via the UPS pathway34,36, we also
wished to test whether the CSN3-dependent stabilization of
Sos1 could be mechanistically linked to processing of Sos1
protein through the 26S proteasome pathway. For this
purpose, mSos2-KO MEFs cells were treated with protea-
some inhibitor MG132 in conjunction with CHX for 9 h,
and the rate of Sos1 protein decay was monitored by means
of immunoblot analysis (Fig. 3d). Quantitation of the WB
data showed that treatment of these MEFs with MG132 for
9 h protected Sos1 from degradation in the presence of
Fig. 3 CSN3 depletion decreases the level of mSos1 in MEFs Sos2-KO and inhibition of proteasome prevents this decay. Sos2-KO MEFs were
transfected with 60 nM either control siRNA scramble (siRNA control), or a pool of four specific CSN3 siRNA (siRNA CSN3). 48 h after the transfection
the cells were treated with cycloheximide 10 µg/ml up to 9 h. a Quantitation of CSN3 protein normalized to the PKCα levels, average of three sets of
experiments (four time-points each). b Endogenous Sos1, CSN3, and PKCα levels were assessed to different times by immunoblotting with specific
antibodies after whole-cell extracts were resolved by SDS-PAGE. The result shown is representative of three separate assays. c Quantitation of mSos1
protein levels normalized to the PKCα levels. The histograms represent the average and SD of three separate assays. d Sos2-KO MEFs were transfected
with either 60 nM control siRNA scramble (siRNA control), or specific CSN3 siRNAs (siRNA CSN3). Forty-eight hours after the transfection, the cells
were treated as indicated with cycloheximide (10 µg/ml) and/or MG132 (10 µM) up to 9 h. The endogenous levels of Sos1, CSN3, and PKCα were
detected by immunoblotting with specific antibodies after the whole cell extracts were resolved by SDS-PAGE. The result shown is representative of
three separate assays. e Quantitation of mSos1 protein levels normalized to the PKCα levels. The histogram represents the average and SD of three
separate assays. f RasGTP formation after CSN3 silencing. The level of RasGTP formed after stimulation of CSN3-silenced or control Sos2-KO MEFs
treated with FGF (25 ng/ml) for the times (min) indicated were followed by means of immunoblotting using specific anti-RasGTP, anti-pan-Ras, anti-
CSN, or anti-B-actin antibodies. g Quantitation of RasGTP levels after normalization to total cellular Ras. The histogram represents the average of three
separate experiments
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CHX. Indeed, when CSN3 expression was silenced by
specific siRNAs, the relative Sos1 protein levels were
reduced to about 34% as compared with the same MEFs
treated with CHX in the absence of MG132 (Fig. 3d, e).
It was also apparent that the reduced cellular levels of
Sos1 detected after CSN3 silencing had relevant func-
tional consequences at the level of cellular physiology, as
shown by the significant reduction of the rate of RasGTP
formation measured upon FGF stimulation in CSN3-
siRNA-silenced cells as compared with control mSos2-
KO MEFs (Fig. 3f, g).
These observations suggest that the interaction between
Sos1 and CSN3 protects Sos1 from proteolytic degrada-
tion occurring in cultured MEF cells through the 26 S
proteasome pathway, and that this interaction may be
functionally relevant.
CSN3-associated kinase PKD phosphorylates Sos1 protein
in vitro
Like other cellular kinases, protein kinase D (PKD) was
reported to be associated to the COP9 signalosome
complex27,37,38 through its interaction with CSN327. In
order to determine whether PKD is able to phosphorylate
Sos1, anti-AU5 immunoprecipitates of lysates of
HEK293T cells previously transfected transiently with
constructs coding for full-length (AU5-hSos1) or HD-
truncated (AU5-hSos1-ΔHD) forms of human Sos1 pro-
teins were used as substrates for in vitro kinase assays
with PKD-KD (kinase dead) and PKD-CA (constitutively
active) mutants of PKD (Fig. 4a). Our assays showed clear
phosphorylation of both hSos1 protein forms (both the
WT and the mutant lacking the HD domain) in the pre-
sence of the constitutively active mutant of PKD (PKD-
CA). In contrast, our data showed absence of phosphor-
ylation of the hSos1 protein forms when the assays were
performed in the presence of the kinase-dead mutant
PKD-KD (Fig. 4a). Consistent with previous reports39,40,
our assays also detected autophosphorylation of the PKD-
CA protein form (Fig. 4a).
Potential matches for the consensus substrate target
motif (L/I-X-R-X-X-S/T) recognized by PKD41,42 are
located within various regions of Sos1, including the REM
and CDC25H motifs (perfect matches at positions T605,
T789, and S921) or the DH region (imperfect matches at
positions S385 and S401). Given the known conforma-
tional interactions between the HD and the DH-PH
motifs, it will be important to test in future the phos-
phorylation status of individual mutations at each of those
positions to determine the exact mechanistic contribution
of their potential phosphorylation to cellular Sos1 stability.
Knockdown of all cellular PKD forms (1, 2, and 3) reduces
Sos1 protein stability
As PKD1 is able to phosphorylate the Sos1 protein in vitro
and is also known to associate with the COP9 signalosome
via its interaction with CSN327, we wished to explore further
the potential in vivo relationship between PDK activity and
cellular Sos1 protein homeostasis.
For this purpose, we knocked-down PKD expression in
mSos2-KO MEFs using specific siRNAs and then tested
the level of Sos1 protein and various related cellular
kinases by means of WB immunoassays using specific
antibodies (Fig. 5). Our previous qRT-PCR analyses of the
expression levels of the three members of the PKD family
(PKD1, PKD2, and PKD3) showed high levels of expres-
sion of the PKD1 and PKD3 forms, whereas PKD2 was
not expressed in these MEFs (data not shown). However,
for these experiments, we chose to use siRNAs directed at
silencing all three PKD isoforms so as to try and prevent
any potential PKD2 expression that might occur as pos-
sible rebound/feedback consequence of reducing levels of
the other two isoforms. Thus, PKD1/2/3 siRNAs were
transiently transfected into MEFs and, after treatment of
the transfected cells with CHX for 9 h, the endogenous
level of mSos1 protein was evaluated at different time
points by WB using anti-Sos1 antibody (Fig. 5a). Quan-
titation of our data clearly showed that, after 9 h of pro-
tein synthesis blockade, the level of mSos1 protein in the
PKD-knocked-down MEFs cells was significantly decayed
(about 50%) in comparison with cells transfected with
control siRNA scramble (Fig. 5b), indicating that COP9
signalosome-associated-PKD kinase plays a role in in vivo
regulation of mSos1 protein stability in these cells.
Discussion
The proteins of the mammalian Sos family are com-
posed by a linear sequence of functionally distinct mod-
ular domains. In this report, we focused on the N-
terminal region of Sos1, encompassing the histone-like
Fig. 4 PKD phosphorylates cellular Sos1. a HEK293T cells were
transfected with 5 µg of AU5-hSos1, AU5-hSos1-ΔHD, pEFBOS-GFP-
PKD1-KD, or pEFBOS-GFP-PKD1-CA. After 48 h transfection, all cells
were serum-starved for 18 h, and 200 µg of whole-cell extracts were
immunoprecipitated with anti-AU5 and anti-PKD antibodies. b The
expression levels of transfected proteins were detected by
immunoblotting with specific antibodies after whole-cell extracts (WE)
were resolved by SDS-PAGE. In vitro kinase assays were performed on
the immunoprecipates as described in Materials and methods
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domain (HD), the Dbl-homology domain (DH), the
pleckstrin domain (PH), and the helical linker (HL)5,6. A
role of this region in intramolecular regulation of Sos GEF
activity has been previously recognized18,19, but its overall
functional relevance is not yet fully understood, and var-
ious regulatory questions concerning the domains within
this region remain unclear.
Looking for cellular proteins with putative binding
affinity for the N-terminal region of Sos1, we carried out a
yeast two-hybrid screening of a HeLa cDNA expression
library and found strong positive interaction between
CSN3 and the Sos1 histone-like domain (HD). This
binding was confirmed in vitro by pull-down experiments
with GST-fusion proteins and in vivo by means of co-
immunoprecipitation assays in lysates of mouse and
human cell lines, thus confirming the occurrence in
eukaryotic cells of direct physical interaction between
CSN3, a subunit of the COP9 signalosome, and the HD
motif of Sos1. Further studies will be needed in future to
pinpoint more accurately the exact region within the HD
that is involved in this interaction and also to ascertain
whether the highly homologous Sos2 proteins43 are also
able to interact with the COP9 signalosome.
The HD contains two tandem histone folds and exerts
negative control on the overall Ras-GEF activity of Sos1
under basal conditions6. Previous structural studies
showed that the HD is conformationally coupled to the
DH-PH unit, therefore stabilizing the auto-inhibited con-
formation of Sos1, in which the DH-PH domain is also
known to interfere with the allosteric binding motif for
Ras17,22. Only upon ligand stimulation of upstream tyr-
osine kinase receptors (RTK), the second phase of Sos
activation—(i) recruitment to the plasma membrane
(involving PH binding to membrane phosphoinositides
and electrostatic interaction between a positively charged
patch of the HD and the negatively charged membrane)
and (ii) disruption of the auto-inhibited conformation
mediated by the DH-PH unit— can take place. Once in the
membrane, the reoriented Sos molecules, displaying
increased accessibility to both of its allosteric and catalytic
Ras binding sites, can processively catalyze nucleotide
exchange on multiple Ras molecules. Various mutations
associated with Noonan syndrome, a disease caused by
hyperactivated Ras signaling, are located in the HD and the
PH domains6,17,22,44,45. Intramolecular interaction between
the HD and the HL, located between PH and REM
domains, may also contribute to maintain the inactive,
auto-inhibited conformation of Sos since a mutation in the
HL (R552G) increases the nucleotide dissociation rate of
Ras and the mutated HL does not interact with the
HD22,46,47. It will be interesting to determine in future
whether or not any of the known Noonan HD mutations
may affect the Sos1-CSN3 interaction in vivo.
Our observations characterizing the interaction
between CSN3 and the Sos1 HD suggest that this domain
not only functions regulating Sos-GEF autoinhibition but
is also involved in other functional roles, such as the
control of Sos protein stability and homeostasis by mod-
ulating the degradation and intracellular levels of Sos1.
On one side, our data showed that an in vivo interaction
occurs between the COP9 signalosome and endogenous
full-length Sos1 protein and that such an interaction is
probably functionally significant as the interaction
between them is higher upon RTK activation, probably
due to disruption of the auto-inhibited conformation
resulting from competition with, or uncoupling of, the
basal HD/DH-PH interaction. On the other hand, our
two-hybrid and co-immunoprecipitation experiments
demonstrating physical interaction between the CSN3
and Sos1 support the notion of the participation of the
UPS pathway in regulation of the homeostasis and
intracellular levels of Sos1 in eukaryotic cells.
Fig. 5 PKD depletion decreases the level of mSos1 in Sos2-KO MEFs. a MEFs Sos2-KO cells were transfected with 60 nM control siRNA scramble
(siRNA control), or 24 nM siRNAs PKD1 and 24 nM siRNAs PKD3 and 12 nM siRNAs PKD2. After 48 h transfection, the cells were treated with
cycloheximide (10 µg/ml) for 9 h. The endogenous mSos1, PKD1, PKD3, and PKCα levels were detected by immunoblotting with specific antibodies
after whole-cell extracts were resolved by SDS-PAGE. The data shown are representative of three separate assays. b Quantitation of mSos1 protein
levels normalized to the PKCα levels. The histogram represents the average and SD of three separate assays
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The COP9 signalosome(CSN) is a highly conserved,
nine-subunit (CSN1–9) protein complex involved in the
ubiquitin–proteasome system in eukaryotic organ-
isms25,34. CSN serves as a dominant regulator of cullin-
RING ligase family of ubiquitin E3 complexes (CRLs)48
through removal of Nedd8 from cullins26,48,49. All CSN
subunits are essential for full function of the complex and
are produced in free-form before coordinated complex
assembling25,26. Heterozygous deletion of CSN3 is the
molecular cause of Smith–Magenis syndrome that results
in reduction of the amount of the CSN protein complex50,
according to the functional role of CSN3 for the CSN
complex stabilization33.
The CSN is associated with several protein kinases
(CK2, AKT, ATM, PKD) able to modify substrates of the
UPS, therefore affecting the stability of different cellular
proteins25,27,51,52. Specifically, PKD interacts with full-
length CSN3 and modifies CSN727. In addition, CSN-
associated PKD phosphorylates c-Jun and p53; CSN-
mediated phosphorylation targets p53 for degradation by
the UPS but stabilizes c-Jun, and inhibition of CSN-
associated kinases triggers ubiquitin-conjugate formation
and c- the case of Sos1, our data indicate that CSN3-
associated PKD is able to phosphorylate Jun degrada-
tion27. Therefore, CSN acts as a platform recruiting pro-
tein kinases for regulating ubiquitin-conjugate formation
by different E3 ubiquitin ligases25,27. In the case of Sos1,
our data indicate that CSN3-associated PKD is equally
able to phosphorylate the full-length Sos1 or a mutant
lacking the HD domain. We also found that knockdown
of all PKD forms or of CSN3, which destroys the CSN
complex33, increases Sos1 degradation by the 26S-
proteasome pathway. Future mechanistic studies will be
needed to ascertain whether PKD mediates
Sos1 stabilization through direct phosphorylation of the
Sos1 protein at any of its conserved target sites for this
kinase or through its interaction with CSN3 or other
components of the COP9 signalosome. As several con-
sensus PKD phosphorylation sites for Sos1 (positions
T605, T789, and S921) are also conserved in Sos2, these
studies will also be relevant to analyze the possibility of
dual control of the stability of both Sos1/2 isoforms via
signalosome/PKD action.
Taken together, our results strongly suggest that the
CSN/PKD complex is involved in stabilization of Sos1
proteins. Although regulation of CSN-dependent dened-
dylation activity25,27 could be a potential mechanism, the
exact mechanistic details responsible for such a stabili-
zation effect remain to be clarified by future studies. In
any event, our data are consistent with the oncogenic role
proposed for CSN53 and the CSN3 protein54 in different
tumor types, and highlight the possibility that the CSN/
PKD complex might be a potential molecular target for
design of new therapeutic drugs.
Materials and methods
Cell lines, transfections, antibodies, and reagents
NIH3T3 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Paisley, UK) sup-
plemented with 10% calf serum (CS, Invitrogen). Human
HeLa cells, HEK293T cells, and mouse embryonic fibro-
blasts MEFs (WT, Sos1-KO, Sos2-KO, and Sos1/2-
DKO)28,30 were maintained in DMEM supplemented with
10% fetal calf serum (FCS; Invitrogen). Before immuno-
precipitation, Sos1-KO and DKO cells were treated for
9 days with 0.3 µM tamoxifen before lysis. Cultures were
tested routinely to exclude mycoplasma contamination
(Universal Mycoplasma Detection kit, ATCC, Manassas,
VA, USA; #30-1012). Transient transfections of HeLa and
HEK293T cells were performed in p100 plates using Jet-
Pei (Polyplus-Transfection, Illkirch, France). For serum-
starvation cells received DMEM containing 0.5% FBS 24 h
after transfection and were then further incubated for
18 h. Cells were stimulated with 30% FCS for 10min. All
assays were done 48 h after transfection. Monoclonal
mouse antibodies against CSN3, ubiquitin (clone P4D1,
sc-8017) and Sos1, and polyclonal rabbit antibodies
against CSN7a, Sos1 (sc-256), Sos2 (sc-258), PKD1, and
GST, were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Monoclonal rabbit antibody anti-
PKCα, clone M4 was purchased from Millipore; anti-HA
and anti-AU5 monoclonal antibodies from Berkeley
Antibody Company (Berkeley, CA); polyclonal rabbit
antibodies against PKD2 and PKD3 from Cell Signaling;
and polyclonal rabbit antibody against CSN3 was acquired
from Abcam (Ab79698-Cambridge, UK). Bound anti-
bodies were detected in some experiments with secondary
antibodies conjugated with IRDye680 or IRDye800 and
analyzed with an Odyssey Imager system (LI-COR, Lin-
coln, NE), or anti-mouse or anti-rabbit horseradish per-
oxidase (1:5000; Bio-Rad) used as a secondary antibody
were visualized using an Enhanced Chemiluminescence
Detection Kit (Amersham, Arlington Heights, IL, USA).
5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-
Gal), 4-hydroxy-tamoxifen(TAM) (H7904), Cyclohex-
imide (C1988) and MG132 (M7449) were from Sigma Co.
(St. Louis, MO, USA). [γ32P]-ATP (370 MBq/ml) was
from PerkinElmer, Inc. (Boston, MA, USA).
DNA constructs
The majority of hSos1 constructs were described pre-
viously55. pCEFL-KZ-AU5-hSos1 was cloned by amplify-
ing hSos1 with specific primers providing Bcl-I and Sma-I
sites at the 5ʹ and 3ʹ ends, respectively, and the amplified
product was subcloned into Bgl-II and Eco-RV sites in
pCEFL-KZ-AU5. To obtain HD-truncated mutant of
hSos1 (pCEFL-KZ-AU5-hSos1-ΔHD), plasmid pCEFL-
KZ-AU5-DH-PH was digested with Hind-III and Spe-I,
and the AU5-DH-PH fragment was subcloned into Hind-
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III and Spe-I sites of pCEFL-KZ-AU5-hSos1. To pre-
viously generate pCEFL-KZ-AU5-DH-PH, the DH-PH
domain of hSos1 (coding region 537–1653) was PCR-
amplified from the pCEFL-KZ-HA-hSos1 plasmid using
specific primers and providing sites BglII and NotI at the
5´ and 3´ ends, respectively. The amplified product was
then subcloned into BglII and NotI sites of vector pCEFL-
KZ-AU555. The HD and NDP domains of hSos1 were
PCR-amplified using the specific primers (corresponding
to coding regions 1–640 and 1–1790, respectively) pro-
viding sites Eco-RI and Sal-I at the 5ʹ and 3ʹ ends,
respectively. The amplified products were then subcloned
into Eco-RI and Xho-I sites in pGEX-4T-1 (Amersham
Biosciences). The DH-PH domain of hSos1 (coding region
537–1653) was PCR-amplified using specific primers
and providing sites Eco-RI and Not-I at the 5ʹ and 3ʹ ends.
The amplified products were then subcloned into Eco-RI
and Not-I sites in pGEX-4T-1. pEFBOS-GFP fused
to PKD1 kinase-dead (single mutant Asp733Ala;
PKD1KD) or constitutively active (double mutant
Ser744/748Glu; PKD1CA) were a gift from T. Iglesias56.
The sequences of the oligonucleotides utilized are
available upon request.
Yeast two-hybrid system
PCR-derived fragments encoding for the appropriate
NDP, HD, DH-PH, DH, PH, and PRII domains (hSos1
coding regions 1–1790, 1–640, 537–1653, 537–1326,
1263–1701, and 1–1790, respectively) were subcloned
into plasmid pEG202, encoding the LexA-binding
domain. The full-coding sequence for CSN3 was cloned
into plasmid pJG45, encoding an amino-terminal B42-
activation domain. Saccharomyces cerevisiae EGY48 strain
(MATα, his3, trp1, ura3-52, leu2: pLEU2-LexAop6) was
used as a host. Co-transformation of two-hybrid vectors
into yeast were performed as described57. Protein–protein
interaction in the two-hybrid system was monitored as
described55.
Immunoprecipitation
Cells treated as indicated in each case were lysed in lysis
buffer and nucleus-free supernatants were incubated with
appropriate antibodies as described55. Immune complexes
were collected by centrifugation, washed five times with
lysis buffer, resolved by SDS-PAGE and visualized by
immunoblotting.
Bacterial expression of fusion proteins
GST-fusion proteins were obtained and purified as
described55. In all binding experiments, transfected
mammalian cells were lysed in lysis buffer55 and 20 μg of
the corresponding GST-fusion proteins, coupled to
glutathione–sepharose beads, were used55.
RNA interference
In knockdown experiments, siRNA duplexes (60 nM)
were transfected twice in MEFs using Lipofectamine
RNAiMAX Reagent (Invitrogen) at 24 h intervals. To
knockdown CSN3 and PKD1/3, we used siGENOME
SMART pool mouse Cops3 (M-047361-00), siGENOME
SMART pool mouse Prkd1 (M-048415-01), siGENOME
SMART pool mouse Prkd2 (M-040693), siGENOME
SMART pool mouse Prkd3 (M-040692-00), and for
siRNA control siGENOME control pool (D-001206-14-
20), all purchased from Dharmacon.
In vitro kinase assays
In vitro kinase assays were performed as described58 by
incubating immunoprecipitated kinase (GFP-PKD-KD or
GFP-PKD-CA) with eluted substrates or AU5-hSos1 or
AU5-hSos1-ΔHD immunoprecipitates in the presence of
ATP-gamma P32.
Statistical analysis
Data were analyzed using GraphPad Prism 7.0. Results
expressed as mean ± SD of the indicated number of
experiments. Statistical significance was evaluated using
the t test for unpaired observations. Western blots were
analyzed using linear correlations between increasing
amounts of protein and signal intensity.
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